Group items tagged

The Neuroendocrine Tumor Research Foundation-AACR Grant represents a joint effort to promote and support innovative cancer research. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to neuroendocrine tumor research.

The Neuroendocrine Tumor Research Foundation-AACR Grant represents a joint effort to promote and support innovative cancer research. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to neuroendocrine tumor research.

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions.

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct health disparities-related meetings, workshops, and symposia. The purpose of the Academic-Community Partnership Conference Series is to bring together academic institutions and community organizations to identify opportunities for reducing health disparities through the use of Community-Based Participatory Research (CBPR). The objectives of meetings conducted as part of this award will be to: (1) establish and/or enhance existing academic-community partnerships; (2) identify community-driven research priorities; and (3) develop long-term collaborative CBPR research agendas. Thus, it is expected these partnerships will lead to grant applications for the support of CBPR projects designed to meet identified community needs. The areas of focus for these partnerships may include one or more of the following community-health issues: preterm birth; infant mortality; sudden infant death syndrome (SIDS); maternal mortality; reproductive health; uterine fibroid tumors; childhood, adolescent, and/or adult obesity; violence prevention; perinatal HBV and HIV/AIDS prevention; HIV/AIDS prevention; asthma; intellectual and developmental disabilities; pediatric injury prevention; and medical rehabilitation.

This year, PCAN has partnered with the Celgene Corporation to accelerate the development of novel therapies by establishing strong relationships between academia and industry through research grants. Funded projects will benefit from industry input and insight, leading to an accelerated translation to a therapeutic product. Projects should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. Of particular interest are projects that fall into at least one of these three areas of research: a) immune context and tumor micro-environment interactions; (b) regulators of pathogenesis, progression, and metabolism, with particular interest in epigenetic mechanisms; and (c) transcriptional networks essential for viability and maintenance of malignant phenotype.

The purpose of this FOA is to support improved cancer immunotherapy research projects that reduce the incidence and/or severity of immune-related adverse events (irAEs) while retaining anti-tumor efficacy. Single investigators and/or multidisciplinary teams with expertise in mechanisms of cancer immunology, immune tolerance, irAEs, autoimmunity, and/or patient characterization and selection are encouraged to propose projects that utilize appropriate model systems, clinical samples, and expertise of these research communities. The specific objectives are to generate new ideas and approaches to better understand and thereby reduce the incidence and/or severity of irAEs resulting from cancer immunotherapy.

The Brander Beacons Cancer Research awards grants in the memory of Christopher E. Brander, the inventor of the LOCalizer™ from Health Beacons, a medical device that revolutionized the standard of care for marking breast lesions for surgical removal. BBCR works to advance its mission in four principal ways: supporting academic research institutions as they research tools and techniques that can increase the accuracy of and improve outcomes in biopsies and tumor removal procedures; identifying ways to improve patient outcomes and access; investing in emerging research and researchers; and serving as an active contributor to the culture of access and innovation in cancer care. To that end, BBCR is accepting applications from organizations doing breakthrough research focused on the prevention, treatment, and cures for breast and prostate cancer.

Centers for Disease Control and Prevention (CDC) supports a variety of activities in health departments and organizations aimed at preventing and controlling cancer, the second leading cause of death in US men and women. Since the passage of the Cancer Registries Amendment Act in 1992, the National Program of Cancer Registries (NPCR) has collected data on cancer occurrence, extent, treatment and outcomes in over 45 states and jurisdictions, representing 96% of the US population. CDC's Division of Cancer Prevention and Control (DCPC) has supported successful partnerships with national organizations to define standardized practices in U.S. cancer surveillance and assure and complete, timely, and high-quality data for the official federal U.S. Cancer Statistics. The purpose of this funding opportunity is to build strong partnerships among national organizations involved directly in cancer surveillance in order to enhance the data quality and operational efficiency of CDC’s National Program of Cancer Registries (NPCR). This program has three essential components: 1) Education, Translation and Quality Control of cancer surveillance standards and best practices; 2) Cancer Staging Collaboration and Support; and 3) Standardization and Support for Laboratory and Biomarker Electronic Reporting. The overarching goal of this project is to collaboratively define and promote uniform standards in cancer staging, collection and reporting. Funded entities will identify specific enhancement needs of cancer registries and support cancer surveillance professionals, including reporters (e.g. facilities, labs), tumor registrars, and registries to submit high quality, standardized data via central cancer registries to NPCR. Relevant performance measures will be used to assess the recipients’ activities that enhance the standards, quality, and operations of NPCR cancer surveillance system.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to establish a Cancer Immunotherapy Consortium (CIC) composed of organ site-specific Cancer Immunotherapy Research Projects as a component of the Immuno-Oncology Translation Network (IOTN). The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.